The Protective Effect of a Long-Acting and Multi-Target HM-3-Fc Fusion Protein in Rheumatoid Arthritis.
International journal of molecular sciences
Huang R, Li J, Wang Y, Zhang L, Ma X, Wang H, Li W, Cao X, Xu H, Hu J.
Publication Overview
Key findings, Countstar context, and access to the original paper.
2018
Bioprocessing
No items found.
Key Finding
Preliminary pharmacokinetic studies in cynomolgus confirmed that the in vivo half-life of HM-3-Fc was 15.24 h in comparison with 1.32 min that of HM-3, which demonstrated that an Fc fusion can effectively increase the half-life of HM-3 and make it possible for further reduction of subcutaneous injection frequency.
Countstar Connection
Countstar (model not specified) measured cell numbers in the study's cell samples during quality assessment in the 2018 International journal of molecular sciences study.
